Cancer research is rapidly unraveling the complex roles of genetic mutations in oncology, leading to targeted approaches where molecular pathology plays a critical role in identifying and monitoring treatment responsive populations as well as in discovering new therapeutic targets. There is a growing need for novel methods like next generation sequencing (NGS) based assays that are rapid, scalable, and capable of detecting a wide range of mutation types.
Enzymatics’ workshop will focus on the application of NGS assays based on Anchored Multiplex PCR (AMP™) technology, a new approach to target enrichment for sensitive detection of gene rearrangements, single nucleotide variants, insertions, deletions, copy number variants or changes in RNA abundance. Conference attendees can register at www.enzymatics.com/agbt-registration.
Presentations and featured speakers are:
In its 15th year, AGBT brings together scientific leaders from various disciplines that are being advanced by DNA sequencing and genome exploration. The conference is recognized throughout the sequencing community as the cornerstone for the discussion of genomics research, providing an excellent forum for exchanging innovations in sequencing technologies and applications. Follow developments at AGBT 2014 on Twitter with #ABGT14.
Enzymatics is a leading producer of sample preparation reagents, assays, kits and software for life science research and applied science customers worldwide. We are experts in the fields of DNA sequencing and PCR, and our business units include:
- Applied Science
Our passion for quality, responsiveness and flexibility is catalyzing the genomic healthcare revolution. www.enzymatics.com